ABALLI JOHN Insider Trading Activity

Average Profitability

<0.0001%

Insider Buys Quantity

Insider Buys Sum

$387,066.97

Insider Sells Quantity

Insider Sells Sum

$59,017.54

Insider Activity of ABALLI JOHN

According to the SEC Form 4 filings, ABALLI JOHN, being in a position of

President and CEO at Exagen Inc.,
оver the last 12 months, has bought 0 shares, and sold 61422 shares for $367,880,
over all time since 2022-12-08, has bought 154706 shares for $387,067, and sold 127028 shares for $802,496.

Biography of ABALLI JOHN

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks


Buys	$0	0	0
Sells	$367,880	3	100

Comparison of Insiders on Amount of Buys and Sells

Sector

Industry

Transaction Type

Transaction Date

From

Total Value


2026-10-16	Sale	Exagen Inc. XGN	President and CEO	34,294 0.1443%	$7.87	$269,791	+1.42%
2026-03-03	Sale	Exagen Inc. XGN	President and CEO	15,698 0.0706%	$3.62	$56,827	+34.69%
2026-02-24	Sale	Exagen Inc. XGN	President and CEO	11,430 0.0493%	$3.61	$41,262	+23.85%
2025-10-16	Sale	Exagen Inc. XGN	President and CEO	31,787 0.145%	$11.82	$375,598	-59.3%
2024-11-14	Purchase	Exagen Inc. XGN	President and CEO	24,305 0.1336%	$2.81	$68,297	+124.48%
2024-05-16	Purchase	Exagen Inc. XGN	President and CEO	40,401 0.2429%	$1.92	$77,570	+64.55%
2023-10-17	Sale	Exagen Inc. XGN	President and CEO	33,819 0.1967%	$1.75	$59,018	+14.88%
2022-12-08	Purchase	Exagen Inc. XGN	President and CEO	90,000 0.5494%	$2.68	$241,200	-2.72%

Total: 8

Company

About Prismo.pro Ideas Articles Privacy Policy Terms of Service Contact Us

Screener Ideas

Dividend Stocks Blue Chip Stocks Defensive Stocks Growth Stocks Value Stocks Cyclical Stocks Penny Stocks

Stock Tools

Insiders Screener Stocks Screener Top Stocks Stock News Insider Ratio List of All Stocks

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.